Eisai hands off responsibility for Aduhelm to Biogen
Summary : –Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over…
Summary : –Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over…
Summary The U.S. Centers for Medicare & Medicaid Services (CMS) just completed the open comment period for their draft national coverage decision…
Summary – The House Energy and Commerce Committee’s health panel met to discuss renewing user fee agreements used to fund the U.S.…
Synopsis: After a special meeting, the Japanese drug reviewers ruled that existing data didn’t support an approval and are therefore seeking additional…
Keypoints Albaugh announced the EPA registration of Anchor™ 3L ST in multiple crop segments as a new fungicide seed treatment offer. Anchor™…